ClinicalTrials.gg
CompletedNCT06166992Updated Nov 9, 2026Results posted

A Study in Healthy Men to Test How BI 1291583 is Taken up by the Body

A Phase 1 interventional study of BI 1291583 and [14C]-BI 1291583 in Healthy, sponsored by Boehringer Ingelheim. Completed at 1 site in Netherlands. Open to male participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-09.

Sponsored by Boehringer Ingelheim · Phase 1, Interventional, and Treatment

Updated Nov 9, 2026Results postedStudy documents posted+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
14
Allocation
Non-randomized
Ages
18 Years to 55 Years
Sex
Male
01

Study summary

The main objective of this trial is to investigate the absolute bioavailability of BI 1291583 (test treatment T, not radio-labelled) compared with BI 1291583 (C-14) (reference treatment R).

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Boehringer Ingelheim is the lead sponsor of 2,305 studies on the registry; 62 are open to participants now.

Of its 169 completed or terminated interventional studies of FDA-regulated products, 123 (73%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Healthy male subjects according to the assessment of the investigator, as based on a complete medical history including a physical examination, vital signs (blood pressure (BP), pulse rate (PR)), 12-lead (ECG), and clinical laboratory tests
  2. Age of 18 to 55 years (inclusive)
  3. (BMI) of 18.5 to 29.9 kg/m2 (inclusive)
  4. Signed and dated written in accordance with ICH-GCP and local legislation prior to admission to the trial.

Exclusion criteria

Exclusion Criteria:

  1. Any finding in the medical examination (including BP, PR or ) deviating from normal and assessed as by the investigator
  2. Repeated measurement of systolic blood pressure outside the range of 90 to 140 mmHg, diastolic blood pressure outside the range of 50 to 90 mmHg, or pulse rate outside the range of 45 to 90 bpm
  3. Any laboratory value outside the reference range that the investigator considers to be of clinical relevance
  4. Any evidence of a concomitant disease assessed as clinically relevant by the investigator
  5. Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological or hormonal disorders
  6. Cholecystectomy or other surgery of the gastrointestinal tract that could interfere with the pharmacokinetics of the trial medication (except appendectomy or simple hernia repair)
  7. Diseases of the central nervous system (including but not limited to any kind of seizures or stroke), and other relevant neurological or psychiatric disorders
  8. History of relevant orthostatic hypotension, fainting spells, or blackouts Further exclusion criteria apply.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
14 participants (actual)

Study arms

  • Experimental
    1 mg BI 1291583 tablet (T1), then 50 μg BI 1291583 (C-14) i.v. (R1)

    Drug: BI 1291583 · Drug: [14C]-BI 1291583

  • Experimental
    5 mg BI 1291583 tablet (T5), then 50 μg BI 1291583 (C-14) i.v. (R5)

    Drug: BI 1291583 · Drug: [14C]-BI 1291583

Interventions

06

What researchers measure

Primary outcomes

  1. Area Under the Concentration-time Curve of BI 1291583/[14C]-BI 1291583 Over the Time Interval From 0 Extrapolated to Infinity - Dose Normalized

    This outcome measured the area under the concentration-time curve over the time interval from 0 extrapolated to infinity (AUC0-∞) of intravenous (i.v.) \[14C\]-BI 1291583 and of BI 1291583 1 milligrams (mg) or 5 mg after oral administration. The AUC0-∞ is presented normalized by the dose administered. The statistical model was an analysis of variance (ANOVA) including 'treatment' as a fixed effect and 'subject' as a random effect. The time frame for analysis of \[14C\]-BI 1291583 in the reference groups R1 and R5 was 9 hours before, immediately before and 0.08, 0.17, 0.25, 0.5, 2, 4, 6, 8, 18, 42, 66, 138 and 210 hours after i.v. administration. The time frame for analysis of BI 1291583 in the test groups T1 and T5 was 3 hours before and 1, 1.5, 2, 3, 4, 6, 6.5, 8, 10, 12, 14, 24, 48, 72, 144 and 216 hours after oral administration.

    Time frame: Up to 219 hours. The detailed timeframe is in the outcome description.

Secondary outcomes

  1. Maximum Measured Concentration of BI 1291583/[14C]-BI 1291583 in Plasma (Cmax) - Dose Normalized

    This outcome measured the maximum concentration in plasma (Cmax) of intravenous (i.v.) \[14C\]-BI 1291583 and of BI 1291583 1 milligrams (mg) or 5 mg after oral administration. The Cmax is presented normalized by the dose administered. The statistical model was an analysis of variance (ANOVA) including 'treatment' as a fixed effect and 'subject' as a random effect. The time frame for analysis of \[14C\]-BI 1291583 in the reference groups R1 and R5 was 9 hours before, immediately before and 0.08, 0.17, 0.25, 0.5, 2, 4, 6, 8, 18, 42, 66, 138 and 210 hours after i.v. administration. The time frame for analysis of BI 1291583 in the test groups T1 and T5 was 3 hours before and 1, 1.5, 2, 3, 4, 6, 6.5, 8, 10, 12, 14, 24, 48, 72, 144 and 216 hours after oral administration.

    Time frame: Up to 219 hours. The detailed timeframe is in the outcome description.

  2. Area Under the Concentration-time Curve of BI 1291583/[14C]-BI 1291583 in Plasma Over the Time Interval From 0 to the Last Quantifiable Time Point (AUC0-tz) - Dose Normalized

    This outcome measured the area under the concentration-time curve in plasma over the time interval from 0 to the last quantifiable time point (AUC0-tz) of intravenous (i.v.) \[14C\]-BI 1291583 and of BI 1291583 1 milligrams (mg) or 5 mg after oral administration. The AUC0-tz is presented normalized by the dose administered. The statistical model was an analysis of variance (ANOVA) including 'treatment' as a fixed effect and 'subject' as a random effect. The time frame for analysis of \[14C\]-BI 1291583 in the reference groups R1 and R5 was 9 hours before, immediately before and 0.08, 0.17, 0.25, 0.5, 2, 4, 6, 8, 18, 42, 66, 138 and 210 hours after i.v. administration. The time frame for analysis of BI 1291583 in the test groups T1 and T5 was 3 hours before and 1, 1.5, 2, 3, 4, 6, 6.5, 8, 10, 12, 14, 24, 48, 72, 144 and 216 hours after oral administration.

    Time frame: Up to 219 hours. The detailed timeframe is in the outcome description.

07

Results

Posted Nov 9, 2026

Participant flow

Non-randomised, open-label, 2-arm, single period trial in healthy male participants to investigate the absolute bioavailability of BI 1291583 administered as tablet (test treatment - T - not radio-labeled) compared with BI 1291583 (C-14) (reference treatment - R) administered as intravenous (i.v.) microtracer. Participants were assigned to one of 2 dose groups, either 1 mg or one 5 mg BI 1291583 tablet followed by the reference treatment.

Participant flow — Overall Study
Milestone1 mg BI 1291583 Tablet (T1), Then 50 μg BI 1291583 (C-14) i.v. (R1)5 mg BI 1291583 Tablet (T5), Then 50 μg BI 1291583 (C-14) i.v. (R5)
Started77
Completed77
Not completed00

Outcome measures

PrimaryArea Under the Concentration-time Curve of BI 1291583/[14C]-BI 1291583 Over the Time Interval From 0 Extrapolated to Infinity - Dose Normalized

This outcome measured the area under the concentration-time curve over the time interval from 0 extrapolated to infinity (AUC0-∞) of intravenous (i.v.) \[14C\]-BI 1291583 and of BI 1291583 1 milligrams (mg) or 5 mg after oral administration. The AUC0-∞ is presented normalized by the dose administered. The statistical model was an analysis of variance (ANOVA) including 'treatment' as a fixed effect and 'subject' as a random effect. The time frame for analysis of \[14C\]-BI 1291583 in the reference groups R1 and R5 was 9 hours before, immediately before and 0.08, 0.17, 0.25, 0.5, 2, 4, 6, 8, 18, 42, 66, 138 and 210 hours after i.v. administration. The time frame for analysis of BI 1291583 in the test groups T1 and T5 was 3 hours before and 1, 1.5, 2, 3, 4, 6, 6.5, 8, 10, 12, 14, 24, 48, 72, 144 and 216 hours after oral administration.

Time frame:
Up to 219 hours. The detailed timeframe is in the outcome description.
Reported as:
Geometric least squares mean · hour*millimole/liter/kilogram
Area Under the Concentration-time Curve of BI 1291583/[14C]-BI 1291583 Over the Time Interval From 0 Extrapolated to Infinity - Dose Normalized
hour*millimole/liter/kilogram1 mg BI 1291583 Tablet - T150 μg BI 1291583 (C-14) i.v. - R15 mg BI 1291583 Tablet - T550 μg BI 1291583 (C-14) i.v. - R5
Area Under the Concentration-time Curve of BI 1291583/[14C]-BI 1291583 Over the Time Interval From 0 Extrapolated to Infinity - Dose Normalized14.50 ± NA26.35 ± NA19.65 ± NA32.70 ± NA
Statistical analysis
  • 1 mg BI 1291583 Tablet - T1 vs 50 μg BI 1291583 (C-14) i.v. - R1 · Adjusted gmean ratio t1/r1 [%]: 55.03 · 90% CI 41.17 to 73.55Adjusted geometric mean (gMean) ratio was calculated as T1/R1\*100.
  • 5 mg BI 1291583 Tablet - T5 vs 50 μg BI 1291583 (C-14) i.v. - R5 · Adjusted gmean ratio t5/r5 [%]: 60.9 · 90% CI 51.51 to 70.9Adjusted geometric mean (gMean) ratio was calculated as T5/R5\*100.
SecondaryMaximum Measured Concentration of BI 1291583/[14C]-BI 1291583 in Plasma (Cmax) - Dose Normalized

This outcome measured the maximum concentration in plasma (Cmax) of intravenous (i.v.) \[14C\]-BI 1291583 and of BI 1291583 1 milligrams (mg) or 5 mg after oral administration. The Cmax is presented normalized by the dose administered. The statistical model was an analysis of variance (ANOVA) including 'treatment' as a fixed effect and 'subject' as a random effect. The time frame for analysis of \[14C\]-BI 1291583 in the reference groups R1 and R5 was 9 hours before, immediately before and 0.08, 0.17, 0.25, 0.5, 2, 4, 6, 8, 18, 42, 66, 138 and 210 hours after i.v. administration. The time frame for analysis of BI 1291583 in the test groups T1 and T5 was 3 hours before and 1, 1.5, 2, 3, 4, 6, 6.5, 8, 10, 12, 14, 24, 48, 72, 144 and 216 hours after oral administration.

Time frame:
Up to 219 hours. The detailed timeframe is in the outcome description.
Reported as:
Geometric least squares mean · picomole/liter/microgram
Maximum Measured Concentration of BI 1291583/[14C]-BI 1291583 in Plasma (Cmax) - Dose Normalized
picomole/liter/microgram1 mg BI 1291583 Tablet - T150 μg BI 1291583 (C-14) i.v. - R15 mg BI 1291583 Tablet - T550 μg BI 1291583 (C-14) i.v. - R5
Maximum Measured Concentration of BI 1291583/[14C]-BI 1291583 in Plasma (Cmax) - Dose Normalized0.32 ± NA27.21 ± NA0.53 ± NA24.05 ± NA
Statistical analysis
  • 1 mg BI 1291583 Tablet - T1 vs 50 μg BI 1291583 (C-14) i.v. - R1 · Adjusted gmean ratio t1/r1 [%]: 1.19 · 90% CI 0.89 to 1.59Adjusted geometric mean (gMean) ratio was calculated as T1/R1\*100.
  • 5 mg BI 1291583 Tablet - T5 vs 50 μg BI 1291583 (C-14) i.v. - R5 · Adjusted gmean ratio t5/r5 [%]: 2.22 · 90% CI 1.39 to 3.55Adjusted geometric mean (gMean) ratio was calculated as T5/R5\*100.
SecondaryArea Under the Concentration-time Curve of BI 1291583/[14C]-BI 1291583 in Plasma Over the Time Interval From 0 to the Last Quantifiable Time Point (AUC0-tz) - Dose Normalized

This outcome measured the area under the concentration-time curve in plasma over the time interval from 0 to the last quantifiable time point (AUC0-tz) of intravenous (i.v.) \[14C\]-BI 1291583 and of BI 1291583 1 milligrams (mg) or 5 mg after oral administration. The AUC0-tz is presented normalized by the dose administered. The statistical model was an analysis of variance (ANOVA) including 'treatment' as a fixed effect and 'subject' as a random effect. The time frame for analysis of \[14C\]-BI 1291583 in the reference groups R1 and R5 was 9 hours before, immediately before and 0.08, 0.17, 0.25, 0.5, 2, 4, 6, 8, 18, 42, 66, 138 and 210 hours after i.v. administration. The time frame for analysis of BI 1291583 in the test groups T1 and T5 was 3 hours before and 1, 1.5, 2, 3, 4, 6, 6.5, 8, 10, 12, 14, 24, 48, 72, 144 and 216 hours after oral administration.

Time frame:
Up to 219 hours. The detailed timeframe is in the outcome description.
Reported as:
Geometric least squares mean · hour*millimole/liter/kilogram
Area Under the Concentration-time Curve of BI 1291583/[14C]-BI 1291583 in Plasma Over the Time Interval From 0 to the Last Quantifiable Time Point (AUC0-tz) - Dose Normalized
hour*millimole/liter/kilogram1 mg BI 1291583 Tablet - T150 μg BI 1291583 (C-14) i.v. - R15 mg BI 1291583 Tablet - T550 μg BI 1291583 (C-14) i.v. - R5
Area Under the Concentration-time Curve of BI 1291583/[14C]-BI 1291583 in Plasma Over the Time Interval From 0 to the Last Quantifiable Time Point (AUC0-tz) - Dose Normalized9.12 ± NA17.53 ± NA18.57 ± NA30.66 ± NA
Statistical analysis
  • 1 mg BI 1291583 Tablet - T1 vs 50 μg BI 1291583 (C-14) i.v. - R1 · Adjusted gmean ratio t1/r1 [%]: 52.04 · 90% CI 43.67 to 62.00Adjusted geometric mean (gMean) ratio was calculated as T1/R1\*100.
  • 5 mg BI 1291583 Tablet - T5 vs 50 μg BI 1291583 (C-14) i.v. - R5 · Adjusted gmean ratio t5/r5 [%]: 60.58 · 90% CI 51.43 to 71.37Adjusted geometric mean (gMean) ratio was calculated as T5/R5\*100.

Adverse events

Collected over All-cause mortality: From first drug administration to individual end of study. Up to day 14. Adverse event reporting: From first drug administration to last drug administration plus 10 days residual effect period. Up to 10 days and 6 hours.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
1 mg BI 1291583 Tablet (T1), Then 50 μg BI 1291583 (C-14) i.v. (R1)0/7 (0%)0/7 (0%)3/7 (42.9%)
5 mg BI 1291583 Tablet (T5), Then 50 μg BI 1291583 (C-14) i.v. (R5)0/7 (0%)0/7 (0%)7/7 (100%)
Most frequent other events
Showing 10 of 14
Most frequent other events
Event1 mg BI 1291583 Tablet (T1), Then 50 μg BI 1291583 (C-14) i.v. (R1)5 mg BI 1291583 Tablet (T5), Then 50 μg BI 1291583 (C-14) i.v. (R5)
DiarrhoeaGastrointestinal disorders0/73/7
Vessel puncture site haematomaGeneral disorders0/72/7
Catheter site haematomaGeneral disorders0/71/7
FatigueGeneral disorders1/70/7
Infusion site haematomaGeneral disorders0/71/7
Infusion site painGeneral disorders1/70/7
NasopharyngitisInfections and infestations1/70/7
ContusionInjury, poisoning and procedural complications1/70/7
Back painMusculoskeletal and connective tissue disorders0/71/7
Muscle twitchingMusculoskeletal and connective tissue disorders1/70/7

Baseline characteristics

Treated set (TS) - all participants who were treated with at least one dose of trial drug.

Age, Continuous
Age, Continuous(Years)1 mg BI 1291583 Tablet (T1), Then 50 μg BI 1291583 (C-14) i.v. (R1)5 mg BI 1291583 Tablet (T5), Then 50 μg BI 1291583 (C-14) i.v. (R5)Total
Mean21.1 ± 1.625.7 ± 4.623.4 ± 4.1
Sex: Female, Male
Sex: Female, Male(Participants)1 mg BI 1291583 Tablet (T1), Then 50 μg BI 1291583 (C-14) i.v. (R1)5 mg BI 1291583 Tablet (T5), Then 50 μg BI 1291583 (C-14) i.v. (R5)Total
Female000
Male7714
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)1 mg BI 1291583 Tablet (T1), Then 50 μg BI 1291583 (C-14) i.v. (R1)5 mg BI 1291583 Tablet (T5), Then 50 μg BI 1291583 (C-14) i.v. (R5)Total
Hispanic or Latino000
Not Hispanic or Latino7714
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)1 mg BI 1291583 Tablet (T1), Then 50 μg BI 1291583 (C-14) i.v. (R1)5 mg BI 1291583 Tablet (T5), Then 50 μg BI 1291583 (C-14) i.v. (R5)Total
American Indian or Alaska Native000
Asian000
Native Hawaiian or Other Pacific Islander000
Black or African American000
White7613
More than one race011
Unknown or Not Reported000
08

Study locations

1 site
  • ICON
    Groningen, 9728 NZ, Netherlands
09

References and documents

Related links

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No — Clinical studies sponsored by Boehringer Ingelheim, phases I to IV, interventional and non-interventional, are in scope for sharing of the raw clinical study data and clinical study documents. Exceptions might apply, e.g. studies in products where Boehringer Ingelheim is not the license holder; studies regarding pharmaceutical formulations and associated analytical methods, and studies pertinent to pharmacokinetics using human biomaterials; studies conducted in a single center or targeting rare diseases (in case of low number of patients and therefore limitations with anonymization). For more details refer to: https://www.mystudywindow.com/msw/datatransparency

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2023 to primary completion in Feb 2024, 1 month.

Results were first posted in Nov 2026, 2 years 9 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 4, 2023
First posted
Dec 12, 2023
StartActual
Dec 12, 2023
Primary completionActual
Feb 7, 2024
CompletionActual
Feb 7, 2024
Results first posted
Nov 9, 2026
Last update
Nov 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Results posted
posted Nov 9, 2026
Interventions
Arms added: 1 mg BI 1291583 tablet (T1), then 50 μg BI 1291583 (C-14) i.v. (R1)·5 mg BI 1291583 tablet (T5), then 50 μg BI 1291583 (C-14) i.v. (R5); arms removed: BI 1291583 alone (not radio-labelled, low dose) then [14C]-BI 1291583 (radio-labelled)·BI 1291583 alone (not radio-labelled, high dose) then [14C]-BI 1291583 (radio-labelled)
Nov 9, 2026
Primary outcomes
1 edited
What changed in the outcomes
  • EditedArea underUnder the concentrationConcentration-time curveCurve of the analyte overBI 1291583/[14C]-BI 1291583 Over the time interval fromTime Interval From 0 extrapolatedExtrapolated to infinity (AUC0Infinity -∞) Dose NormalizedTime frame: Up to 10 days → Up to 219 hours. The detailed timeframe is in the outcome description.
Nov 9, 2026
Documents
Secondary outcomes
2 edited
What changed in the outcomes
  • EditedMaximum measured concentrationMeasured Concentration of the analyteBI 1291583/[14C]-BI 1291583 in plasmaPlasma (Cmax) - Dose NormalizedTime frame: Up to 10 days → Up to 219 hours. The detailed timeframe is in the outcome description.
  • EditedArea underUnder the concentrationConcentration-time curveCurve of the analyteBI 1291583/[14C]-BI 1291583 in plasma overPlasma Over the time interval fromTime Interval From 0 to the last quantifiable time pointLast Quantifiable Time Point (AUC0-tz) - Dose NormalizedTime frame: Up to 10 days → Up to 219 hours. The detailed timeframe is in the outcome description.
Nov 9, 2026
Show all 1 update
  1. Nov 9, 2026
    Results posted
    Primary outcomes 1 edited
    What changed in the outcomes
    • EditedArea underUnder the concentrationConcentration-time curveCurve of the analyte overBI 1291583/[14C]-BI 1291583 Over the time interval fromTime Interval From 0 extrapolatedExtrapolated to infinity (AUC0Infinity -∞) Dose NormalizedTime frame: Up to 10 days → Up to 219 hours. The detailed timeframe is in the outcome description.
    Secondary outcomes 2 edited
    What changed in the outcomes
    • EditedMaximum measured concentrationMeasured Concentration of the analyteBI 1291583/[14C]-BI 1291583 in plasmaPlasma (Cmax) - Dose NormalizedTime frame: Up to 10 days → Up to 219 hours. The detailed timeframe is in the outcome description.
    • EditedArea underUnder the concentrationConcentration-time curveCurve of the analyteBI 1291583/[14C]-BI 1291583 in plasma overPlasma Over the time interval fromTime Interval From 0 to the last quantifiable time pointLast Quantifiable Time Point (AUC0-tz) - Dose NormalizedTime frame: Up to 10 days → Up to 219 hours. The detailed timeframe is in the outcome description.
    Interventions Arms added: 1 mg BI 1291583 tablet (T1), then 50 μg BI 1291583 (C-14) i.v. (R1)·5 mg BI 1291583 tablet (T5), then 50 μg BI 1291583 (C-14) i.v. (R5); arms removed: BI 1291583 alone (not radio-labelled, low dose) then [14C]-BI 1291583 (radio-labelled)·BI 1291583 alone (not radio-labelled, high dose) then [14C]-BI 1291583 (radio-labelled)
    + 2 other changes: identifiers and verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT06166992
Responsible party
Sponsor
First posted
Dec 12, 2023
Start date
Dec 12, 2023
Primary completion
Feb 7, 2024
Completion
Feb 7, 2024
Results posted
Nov 9, 2026
Last update
Nov 9, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Verducatib

Start the discussion